Sumitomo Pharma Co., Ltd.
25 clinical trials · Sponsor
◉ Watch Sumitomo Pharma Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP (NCT06460064) | Sumitomo Pharma Co., Ltd. | 2024-06-26 |
| A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease (NCT05435729) | Sumitomo Pharma Co., Ltd. | 2022-05-31 |
| A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan (NCT05359081) | Sumitomo Pharma Co., Ltd. | 2022-05-16 |
| Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia (NCT04325737) | Sumitomo Pharma Co., Ltd. | 2020-03-31 |
| Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2). (NCT03370640) | Sumitomo Pharma Co., Ltd. | 2017-11-29 |
Track Sumitomo Pharma Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.